Regulation of immune responses is tightly controlled through a balance of co-stimulatory and inhibitory checkpoint receptors, often exploited by many cancers. Therefore, therapeutics that block inhibitory receptors or activate immune-stimulatory checkpoint receptors are powerful agents to restore anti-tumor immune responses, such as anti-PD-1 therapy. However, developing drugs targeting these checkpoint proteins is quite challenging, as cell-based assays used to screen for functional drugs are often difficult to create, involve the use of primary cells, and have long, complicated protocols. To solve this bottleneck, Eurofins DiscoverX’s iONCscan Services offer an expanding menu of cell-based assays that can enable screening & potency determination for immunotherapy drugs.
Advantages of iONCscan Services for Checkpoint Receptors
- Potency determination – Rank order potency of your molecules
- Fast turnaround time – Obtain results within 30 days without the need to develop and validate assays in-house
- Multiple applications– Can be used for biologic and small molecule drug development
